APIM Therapeutics Competitors and Similar CompaniesClear all

APIM Therapeutics's competitors and similar companies include Fluxion Biosciences, Crown Bioscience, Ecrins Therapeutics and Imugene.

	APIM Therapeutics APIM Therapeutics is a clinical-stage biotech company focusing on the development of treatments in the fields of oncology and inflammation.	Fluxion Biosciences Fluxion Biosciences is a company developing systems for live cell analysis.	Crown Bioscience Crown Bioscience is a company providing drug discovery and development services in the areas of oncology, inflammation, and metabolic diseases.	Ecrins Therapeutics Ecrins Therapeutics is a biotechnology company that focuses on the discovery and development of anti-cancer compounds.	Imugene Imugene is a clinical-stage immuno-oncology company developing cancer treatments.
Founding Date	Founding Date 2010	Founding Date 2005	Founding Date 2006	Founding Date 2010	Founding Date 2013
Type	Type Subsidiary	Type Private	Type Subsidiary	Type Private	Type Public
Tags	Tags Technology biotech clinical research drug development oncology	Tags Healthcare biotech clinical research drug development oncology	Tags biotech clinical research drug development medical diagnostics oncology	Tags Healthcare biotech clinical research drug development oncology	Tags Healthcare biotech clinical research drug development oncology
Locations	Locations Trondheim, NO HQ Rissa, NO	Locations Alameda, US HQ	Locations San Diego, US HQ Suzhou Shi, CN Suzhou Shi, CN Utrecht, NL Loughborough, GB see more	Locations La Tronche, FR HQ	Locations SYDNEY, AU HQ
Employees	Employees 7	Employees 7	Employees 5731% decrease	Employees 1	Employees N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods kr1.2m (FY, 2021)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit (kr1.2m) (FY, 2021)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $4.4m (FY, 2025)
Net income	Net income (kr14.8m) (FY, 2021)	Net income N/A	Net income N/A	Net income N/A	Net income ($69m) (FY, 2025)
Funding
Latest funding round	Latest funding round N/A	Latest funding round $ 280k (over 6 years ago)	Latest funding round N/A	Latest funding round $ 599.1k (almost 11 years ago)	Latest funding round N/A
Total funding raised	Total funding raised N/A	Total funding raised $ 22.5m	Total funding raised $ 62.1m	Total funding raised $ 2.7m	Total funding raised N/A